Colorectal Cancer Test Drives Q4 Revenue Increase for GeneNews | GenomeWeb

NEW YORK (GenomeWeb News) — Molecular diagnostics company GeneNews saw its fourth-quarter revenues rise sharply year over year after its colorectal cancer test was approved for marketing in New York, the company reported after the close of the market on Tuesday.

For the three months ended Dec. 31, 2012, the Toronto-based firm posted revenues of C$59,630 (US$58,658), up from C$2,840 a year ago. Revenues were derived completely from its ColonSentry gene expression assay for assessing a patient's risk for colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.